Overweight and cholesterol - impact on the clinical effects of endocrine treatment in breast cancer

Project: Research

Project Details

Key findings

Paper 1: Statin use was associated with a reduced risk of breast cancer recurrence among postmenopausal patients diagnosed with early stage breast cancer who received adjuvant aromatase inhibitor therapy in a nationwide Danish cohort study.

Paper 2: In a systematic review and meta-analysis we present results identifying that overweight TNBC patients have a poorer breast cancer prognosis, with shorter disease-free and overall survival in comparison with normal-weight TNBC patients. During the follow-up periods, overweight TNBC patients were found to be 29% more likely to die than normal-weight TNBC patients.

Paper 3: High pre-diagnostic levels of Apo B were associated with an increased risk of recurrence among breast cancer patients. The association remained positive for distant recurrences but not for loco-regional recurrences. In the 5-year estimates, patients with high levels of Apo B had a two-fold increased risk of recurrence of their breast cancer versus patients with low levels of Apo B.

Layman's description

Brystkræft er den mest almindelige kræftform blandt kvinder med en støt stigning i antallet kvinder, der rammes; i dag anslås det, at næsten hver ottende kvinde i Danmark på et tidspunkt i livet vil få diagnosen brystkræft. Parallelt er overvægt et voksende problem for folkesundheden i hele verden, herunder Danmark, hvor forekomsten af overvægt er steget markant inden for de seneste årtier.

Forholdet mellem overvægt, forhøjede kolesterolniveauer, og hjerte-kar-sygdomme har gennem lang tid været velkendt, hvilket med succes har ført til sygdomsforebyggende livsstil og medicinering. Derimod er det mindre kendt for offentligheden - og blandt sundhedspersonale og forskningsverdenen som helhed - at omkring 20% af alle kræftdiagnoser skønnes at være relaterede til overvægt. Brystkræft er en af dem. Overvægtige er dobbelt ramte, da brystkræftprognosen har vist sig at være signifikant værre blandt disse
patienter. I det her projekt vil vi undersøge hvis overvægt og kolesterolsænkende medicin påvirker effekten af den antihormonelle behandling majoriteten af brystkræftpatienter tilbydes.
StatusActive
Effective start/end date01/10/201831/08/2026

Funding

  • Institute of Cancer Research, Radiumstationen, Aarhus: DKK40,000.00
  • Aarhus University (AU)

Keywords

  • Breast Cancer
  • Statins
  • Epidemiology
  • Adjuvant Therapy
  • Overweight
  • Obesity
  • Endocrine treatment
  • Aromatase Inhibitors
  • Postmenopausal
  • Cholesterol
  • Apolipoprotein
  • ApoB

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.